Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iSpecimen (ISPC) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to 2608.68%.

  • iSpecimen's EBITDA Margin fell 25545900.0% to 2608.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 343.99%, marking a year-over-year decrease of 2542700.0%. This contributed to the annual value of 134.52% for FY2024, which is 227300.0% down from last year.
  • Latest data reveals that iSpecimen reported EBITDA Margin of 2608.68% as of Q3 2025, which was down 25545900.0% from 146.85% recorded in Q2 2025.
  • In the past 5 years, iSpecimen's EBITDA Margin ranged from a high of 31.81% in Q1 2021 and a low of 2608.68% during Q3 2025
  • For the 5-year period, iSpecimen's EBITDA Margin averaged around 246.6%, with its median value being 93.64% (2022).
  • In the last 5 years, iSpecimen's EBITDA Margin soared by 1455200bps in 2024 and then crashed by -25545900bps in 2025.
  • Quarter analysis of 5 years shows iSpecimen's EBITDA Margin stood at 78.26% in 2021, then rose by 8bps to 72.31% in 2022, then plummeted by -54bps to 111.49% in 2023, then tumbled by -268bps to 409.81% in 2024, then tumbled by -537bps to 2608.68% in 2025.
  • Its EBITDA Margin was 2608.68% in Q3 2025, compared to 146.85% in Q2 2025 and 156.82% in Q1 2025.